Genomic Sequencing Investigation of 733 HER2-amplified primary and metastatic breast tumours revealed major enrichment of mutations that activate RAS–MAPK signalling in Highly developed tumours handled with prior anti-HER2 therapies121. These mutations, such as NF1 and HER2 activating mutations, contribute to resistance to tucatinib and neratinib. Palliative care is usually a https://www.directivepublications.org/journal-of-clinical-breast-cancer/